Navigation Links
VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
Date:5/4/2008

SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN.OB), a biopharmaceutical company, announced today it has completed the sale of all assets and rights related to its recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology to Emergent BioSolutions, Inc. Under the terms of the transaction, Emergent BioSolutions paid VaxGen $2 million upon execution of the definitive agreement and may be obligated to pay up to an additional $8 million in milestone payments, plus specified percentages of future net sales.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

"We have marketed our anthrax vaccine candidate and related technology very broadly over the last 12 months," said James P. Panek, VaxGen President and CEO. "In Emergent, we believe we have identified a partner whose expertise in the field and track record in contracting with government agencies maximizes the chances of returns for our shareholders."

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the potential receipt of milestone payments and specified percentages of future net sales from Emergent BioSolutions. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Additional information concerning these and other risk factors is contained in VaxGen's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward- looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VaxGen and Raven Terminate Merger Agreement
2. VaxGen Issues Rebuttal to MedCap Letter
3. VaxGen Common Stock Now Quoted on OTC Bulletin Board
4. VaxGen Reports Financial Update
5. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
6. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
7. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
8. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
9. VaxGen Addresses MPM Claims in Letter to Stockholders
10. VaxGen Files Last Outstanding Periodic Report With SEC
11. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... ... file transfer solution that makes it easy for organizations to send and gather ... about cumbersome FTP software or email file size limitations. , Using the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a ... anniversary, marking the occasion with a strong presence at Bio-IT World Conference & ... further extends an invitation to all attendees to view posters on the ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Vortex Biosciences ... “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology ” in ... of a collaboration with Dr. Dino Di Carlo and Dr. Matthew Rettig at the ...
(Date:5/23/2017)... ... , ... Bacterial biofilms, surface adherent communities of bacteria that are encased in ... poisoning and catheter infections to gum disease and the rejection of medical implants. ... per year, there is currently a paucity of means for preventing their formation or ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
Breaking Biology News(10 mins):